Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Jul 27, 2023
TickeronGET DAILY SIGNALS

Our Robots Earned Over 4% in 5 Trading Days with $ABBV Stock.

The dynamics in our robots remain impressive, and we comfortably outperform all indices. Today, I would like to highlight one of our robots, Swing-Trader-Popular-Stocks-TA-FA, which specializes in trading stocks with high volatility, particularly like ABBVIE INC. "ABBV."

This robot exhibits significant volatility, which presents excellent opportunities for profitable trading. The average duration of a trade is 19 hours, allowing traders to efficiently utilize their capital and avoid being stuck in trades for extended periods.

The development of this robot involved several steps:

  1. We created a group of highly volatile stocks, forming the universe for the robot.
  2. For each stock in the universe, we created algorithms based on a proprietary combination of technical indicators with individually selected parameters.
  3. Using neural networks, we conducted thousands of backtests to determine the most profitable stocks and best-performing trading systems.
  4. We created a mechanism that enables the robot to automatically choose the most suitable trading system for each stock.

After entering a trade, our AI Robot places a "Take profit" order, the distance of which depends on the current market volatility. To exit a position, the robot employs two options: a stop loss set at 2-4% of the position's opening price and a flexible trailing stop that allows preserving most of the profit if the market reverses.

The robot's trading results are shown without using margin. For complete trading statistics and equity chart, click on the "show more" button on the robot's page. In the "Open Trades" tab, a trader can observe how the AI Robot selects equities, enters and exits paper trades. In the "Closed Trades" tab, users can review all previous trades made by the AI Robot.

We continue to improve and develop our robots to provide traders with tools for successful trading in financial markets. Our team strives to make trading accessible, convenient, and profitable for all our users. Stay tuned for updates and see for yourself the outstanding performance of our robots!

Related Ticker: ABBV

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


ABBV sees MACD Histogram crosses below signal line

ABBV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 03, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 27 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 57%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 18 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABBV as a result. In 36 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +0.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 222 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.

ABBV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 217 of 349 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.421). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.700). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).

The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -13%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -6%. OGN experienced the highest price growth at -0%, while SCLX experienced the biggest fall at -63%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 59%. For the same stocks of the Industry, the average monthly volume growth was 59% and the average quarterly volume growth was 35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 36
Price Growth Rating: 50
SMR Rating: 61
Profit Risk Rating: 61
Seasonality Score: 13 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a research-based pharmaceutical company

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
1 North Waukegan Road
Phone
+1 847 932-7900
Employees
57000
Web
https://www.abbvie.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.